Higher close as bitcoin futures begin trading

The markets advanced to close higher with the Dow gaining 56 points to 24,386 as Cboe Global Markets began trading bitcoin futures. Nasdaq gained 35 points to 6,875.


On the upside


argenx SE (Nasdaq: ARGX) provided an update to its Phase 1/2 clinical trial of ARGX-110 in cutaneous T-cell lymphoma and announced a proposed public offering of $150 million American Depositary Shares.


Blueprint Medicines (Nasdaq: BPMC) reported upbeat new data from an ongoing Phase 1 clinical trial of avapritinib to treat advanced systemic mastocytosis.


Morgan Stanley Investment Management acquired an 11.4% stake in Overstock.com (Nasdaq: OSTK).


On the downside


Spark Therapeutics (Nasdaq: ONCE) reported disappointing preliminary results from a Phase 1/2 clinical trial of SPK-8011 to treat hemophilia A.


Syros Pharmaceuticals (Nasdaq: SYRS) presented disappointing preclinical data from an ongoing Phase 1 clinical trial of SY-1365.


Investors locked in profits on Verastem (Nasdaq: VSTM).


In the broad market, advancing issues outpaced decliners by a margin of nearly 6 to 5 on the NYSE while decliners edged out advancers by nearly 6 to 5 on Nasdaq. The broader S&P 500 gained 8 points to 2,659. Bitcoin vaulted $2,704 to $16,964.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.